UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another
Executive Summary
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
You may also be interested in...
Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial
Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.
In A First, FDA Approves Radioembolization Treatment For Liver Cancer In US
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.